Sigachi Industries Limited (NSE:SIGACHI)
28.44
-0.36 (-1.25%)
Oct 1, 2026, 3:30 PM IST
Sigachi Industries Revenue
Sigachi Industries had revenue of 1.21B INR in the quarter ending June 30, 2026, a decrease of -5.44%. This brings the company's revenue in the last twelve months to 4.71B, down -9.58% year-over-year. In the fiscal year ending March 31, 2026, Sigachi Industries had annual revenue of 4.78B, down -4.50%.
Revenue (ttm)
4.71B
Revenue Growth
-9.58%
P/S Ratio
2.30
Revenue / Employee
3.36M
Employees
1,400
Market Cap
10.83B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.78B | -224.98M | -4.50% |
| Mar 31, 2025 | 5.00B | 962.25M | 23.81% |
| Mar 31, 2024 | 4.04B | 1.02B | 33.79% |
| Mar 31, 2023 | 3.02B | 517.55M | 20.68% |
| Mar 31, 2022 | 2.50B | 544.85M | 27.83% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 18.73B |
| Solara Active Pharma Sciences | 14.31B |
| Windlas Biotech | 9.42B |
| Ind-Swift Laboratories | 6.74B |
| Beta Drugs | 4.10B |
| Valiant Laboratories | 3.06B |
| Jagsonpal Pharmaceuticals | 2.94B |
| Amanta Healthcare | 2.91B |